Movement Alert｜Halozyme Therapeutics Overnight Rise 6.08%, Q2 Earnings Significantly Beat Expectations with Full-Year Guidance Raised

Market Focus08-07

On August 7, Halozyme Therapeutics rose 6.08% overnight, trading at $90.97/share, with turnover of $2,895.

The rally was driven by the company's Q2 earnings report, which significantly exceeded market expectations across all metrics, accompanied by a substantial upward revision of full-year guidance. Q2 adjusted EPS came in at $2.28, beating the analyst consensus estimate of $1.84 by approximately 24%, representing a 48% year-over-year increase. Revenue reached $481 million, surpassing estimates of roughly $407 million by approximately 19%, up 47.7% year-over-year.

The company simultaneously raised its full-year outlook to adjusted EPS of $8.65 to $9.00 on revenue of $1.835 billion to $1.91 billion, well above the prior guidance of $7.75 to $8.25 EPS on $1.71 billion to $1.81 billion in revenue. The updated guidance also meaningfully exceeds analyst consensus estimates of $7.94 EPS and $1.77 billion in revenue, reflecting continued royalty-driven outperformance and strong momentum across its ENHANZE portfolio.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1164618525?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-07 13:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1164618525","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Halozyme Therapeutics Overnight Rise 6.08%, Q2 Earnings Significantly Beat Expectations with Full-Year Guidance Raised","media":"Market Focus","content":"<p><p>On August 7, Halozyme Therapeutics rose 6.08% overnight, trading at $90.97/share, with turnover of $2,895.</p><p>The rally was driven by the company's Q2 earnings report, which significantly exceeded market expectations across all metrics, accompanied by a substantial upward revision of full-year guidance. Q2 adjusted EPS came in at $2.28, beating the analyst consensus estimate of $1.84 by approximately 24%, representing a 48% year-over-year increase. Revenue reached $481 million, surpassing estimates of roughly $407 million by approximately 19%, up 47.7% year-over-year.</p><p>The company simultaneously raised its full-year outlook to adjusted EPS of $8.65 to $9.00 on revenue of $1.835 billion to $1.91 billion, well above the prior guidance of $7.75 to $8.25 EPS on $1.71 billion to $1.81 billion in revenue. The updated guidance also meaningfully exceeds analyst consensus estimates of $7.94 EPS and $1.77 billion in revenue, reflecting continued royalty-driven outperformance and strong momentum across its ENHANZE portfolio.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Halozyme Therapeutics Overnight Rise 6.08%, Q2 Earnings Significantly Beat Expectations with Full-Year Guidance Raised</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Halozyme Therapeutics Overnight Rise 6.08%, Q2 Earnings Significantly Beat Expectations with Full-Year Guidance Raised\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-07 13:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 7, Halozyme Therapeutics rose 6.08% overnight, trading at $90.97/share, with turnover of $2,895.</p><p>The rally was driven by the company's Q2 earnings report, which significantly exceeded market expectations across all metrics, accompanied by a substantial upward revision of full-year guidance. Q2 adjusted EPS came in at $2.28, beating the analyst consensus estimate of $1.84 by approximately 24%, representing a 48% year-over-year increase. Revenue reached $481 million, surpassing estimates of roughly $407 million by approximately 19%, up 47.7% year-over-year.</p><p>The company simultaneously raised its full-year outlook to adjusted EPS of $8.65 to $9.00 on revenue of $1.835 billion to $1.91 billion, well above the prior guidance of $7.75 to $8.25 EPS on $1.71 billion to $1.81 billion in revenue. The updated guidance also meaningfully exceeds analyst consensus estimates of $7.94 EPS and $1.77 billion in revenue, reflecting continued royalty-driven outperformance and strong momentum across its ENHANZE portfolio.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HALO","symbol_name":"奥洛兹美医疗","start_time":0,"source_url":"","article_id":"1164618525","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1164618525","pubTimestamp":1786080062,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 7, Halozyme Therapeutics rose 6.08% overnight, trading at $90.97/share, with turnover of $2,895.The rally was driven by the company's Q2 earnings report, which significantly exceeded market...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HALO":"奥洛兹美医疗"},"translate_title":"走势提醒|Halozyme Therapeutics隔夜上涨6.08%，第二季度盈利大幅超出预期，全年指引上调","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HALO":1},"content_text":"On August 7, Halozyme Therapeutics rose 6.08% overnight, trading at $90.97/share, with turnover of $2,895.The rally was driven by the company's Q2 earnings report, which significantly exceeded market expectations across all metrics, accompanied by a substantial upward revision of full-year guidance. Q2 adjusted EPS came in at $2.28, beating the analyst consensus estimate of $1.84 by approximately 24%, representing a 48% year-over-year increase. Revenue reached $481 million, surpassing estimates of roughly $407 million by approximately 19%, up 47.7% year-over-year.The company simultaneously raised its full-year outlook to adjusted EPS of $8.65 to $9.00 on revenue of $1.835 billion to $1.91 billion, well above the prior guidance of $7.75 to $8.25 EPS on $1.71 billion to $1.81 billion in revenue. The updated guidance also meaningfully exceeds analyst consensus estimates of $7.94 EPS and $1.77 billion in revenue, reflecting continued royalty-driven outperformance and strong momentum across its ENHANZE portfolio.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1164618525","isCrawlerRequest":true}